Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem.
Six healthy male subjects who had received imipenem without cilastatin in previous studies, were given 500 mg meropenem as single 30 min intravenous infusions. Plasma and urine samples were collected for 12 h and meropenem and its metabolite were assayed by HPLC and RIA, respectively. The mean plasma half-life of meropenem was 0.8 h, mean plasma clearance 277 ml/min and the mean volume of distribution 20.4 l. The metabolite reached mean peak plasma concentrations of 1.5 mg/l. Renal clearance of meropenem averaged 200 ml/min. The mean urinary recovery of the metabolite was 20% and of unchanged drug 72% of the dose given. The recovery of meropenem ranged from 62.2% to 78.2% and was correlated to the urinary recovery of imipenem when given without cilastatin to the same subjects in previous studies (range 15.2-32.2%, rank correlation coefficient = 0.934). The results indicate that meropenem is much less susceptible to renal metabolism than imipenem. The inter-subject variability observed with meropenem correlates with the extent of urinary recovery of imipenem observed in previous studies with imipenem alone, indicating some susceptibility of meropenem to renal dehydropeptidase-I.
Burman
L A
LA
Department of Infectious Diseases, University of Umea, Sweden.
Nilsson-Ehle
I
I
Hutchison
M
M
Haworth
S J
SJ
Norrby
S R
SR
D000328:Adult; D004305:Dose-Response Relationship, Drug; D006207:Half-Life; D006801:Humans; D015378:Imipenem / Q000008:administration & dosage / Q000378:metabolism*; D007262:Infusions, Intravenous; D007668:Kidney / Q000378:metabolism*; D008297:Male; D000077731:Meropenem; D008657:Metabolic Clearance Rate; D011758:Pyrroles / Q000493:pharmacokinetics*; D015203:Reproducibility of Results; D013845:Thienamycins / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine
D011758:Pyrroles; D013845:Thienamycins; C069520:ICI 213689; D015378:Imipenem; D000077731:Meropenem